ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1114

Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout

Ying-Chou Chen Sr.1, Shih-Chueh Chen2, Chung-Tei Chou3, Carl Brown4, Jing-Yi Lee4, Wei-Shu Lu5 and Chang Youh Tsai6, 1Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, 2Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, 3Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, 5TWi Biotechnology, Inc., Taipei, Taiwan, 6Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Diacerein, Febuxostat, Gout and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral IL-1β modulator and also discovered to possess uric acid-lowering effects by inhibiting urate transporter 1 (URAT1). This study was a randomized, placebo-controlled multicenter, 16‑week Phase 2 study designed to test the urate-lowering effects, safety and tolerability of diacerein controlled release tablets (CR), which is designed for bioavailability and pharmacokinetic improvement, and adverse effect alleviation as compared with the currently available immediate-release oral formulation.

Methods: The study comprised 4 periods of 4 weeks each: blinded study medication only, combination with febuxostat 40 mg once daily (QD), study medication plus febuxostat with titration to 80 mg febuxostat QD for those not achieving sUA <6 mg/dL, and finally febuxostat alone. A total of 127 subjects with hyperuricemia and gouty arthritis were randomized to diacerein 100 mg or placebo twice daily (BID). Subjects were Asian, primarily male, mean age 47 years, mean duration of gout 8.7 years, and mean sUA 9.0 mg/dL at baseline.

Results: The study was powered to show a difference in proportion of subjects achieving target sUA <6 mg/dL at Week 8 with significance assessed at a 1-sided p-value <0.05. Significantly more diacerein than placebo subjects (64% vs 55%) achieved the endpoint (p = 0.0337). Also, more diacerein subjects achieved sUA <5 mg/dL at Week 8 (39% vs 27%; p=0.0140). The overall flare rate was not different between groups.

There were no serious adverse events in either group; 6% of diacerein subjects withdrew due to an adverse event. The most common adverse events with diacerein were diarrhea (27%) and soft stools (13%).

Conclusion: This study showed that treatment with diacerein 100 mg BID increased the odds of achieving the clinical sUA target of <6.0 mg/dL at Week 8, after 4 weeks of treatment with diacerein alone and 4 weeks of diacerein in combination with 40 mg febuxostat QD. Treatment with diacerein was shown to be safe and well tolerated with no new safety trends noted in this study. In combination with a low-dose xanthine oxidase inhibitor, diacerein could be a potential formulation to increase the percentage of gout patients who reach the sUA target without increasing flare rates.

Table 1. Demographic and Baseline Characteristics

Characteristic

Diacerein
100 mg BID
(N = 67)

Placebo BID
(N = 60)

Age (years) – Mean (SD)

47.2 (11.7)

47.5 (13.1)

Gender – n (%)

Male

62 (92.5)

59 (98.3)

Female

5 (7.5)

1 (1.7)

Race – n (%)

Asian

67 (100)

60 (100)

sUA (mg/dL) at baseline – Mean (SD)

9.1 (1.7)

8.9 (1.5)

Weight (kg) – Mean (SD)

76.6 (12.9)

78.1 (15.0)

Gout duration (yr) – Mean (SD)

9.0 (7.8)

8.3 (8.4)

Flares in prior year – Mean (SD)

3.0 (3.8)

2.2 (2.4)

Subjects w/ tophus – n (%)

6 (9.0)

4 (6.7)

Metabolic disease history – n (%)

41 (61.2)

35 (58.3)

SD = standard deviation.

Table 2. Proportion of Subjects Achieving sUA <6.0 and <5.0 mg/dL at Week 8

Diacerein
100 mg BID
(N = 67)
n/N (%)

Placebo BID
(N = 60)
n/N (%)

p-value

1‑sided

sUA <6.0

43 / 67 (64.2%)

33 / 60 (55.0%)

0.0337

Odds Ratio (95% CI)

2.1069 (0.9508, 4.6687)

sUA <5.0

26 / 67 (38.8%)

16 / 60 (26.7%)

0.0139

Odds Ratio (95% CI)

2.5352 (1.0955, 5.8667)

CI = confidence interval.


Disclosure: Y. C. Chen Sr., None; S. C. Chen, None; C. T. Chou, None; C. Brown, TWi Biotechnology Inc., 3; J. Y. Lee, TWi Biotechnology Inc., 3; W. S. Lu, TWi Biotechnology Inc., 3; C. Y. Tsai, None.

To cite this abstract in AMA style:

Chen YC Sr., Chen SC, Chou CT, Brown C, Lee JY, Lu WS, Tsai CY. Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effects-of-diacerein-controlled-release-tablets-in-serum-uric-acid-reduction-in-treating-subjects-with-gout/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-diacerein-controlled-release-tablets-in-serum-uric-acid-reduction-in-treating-subjects-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology